Symptomata nova, ut visus duplex vel imbecillitas reptentinarepentina, congressionem progressumve morbi suspicionem quaerant tractationemque medicam<ref>{{cite journal |authors=Berkovich R. |title=Treatment of acute relapses in multiple sclerosis |journal=Neurotheraeutics |year=2013 |month=Ian |volume=10 |issue=1 |pages=97-105 |url=https://pubmed.ncbi.nlm.nih.gov/23229226/}}, {{doi|10.1007/s13311-012-0160-7}}</ref>. Medicamenta ordine prima sunt [[glucocorticoidum|glucocorticoida]], ut [[prednisolonum]] vel [[methyloprednisolonum]], quae intra venam applicari solent, at etiam per os sumi queant<ref>{{cite journal |authors=Liu S., Liu X., Chen S., Xiao Y., Zhuang W. |title=Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials |journal=PLoS One |year=2017 |month=Nov |volume=12 |issue=11 |pages=ee0188644 |url=https://pubmed.ncbi.nlm.nih.gov/29176905/}}, {{doi|10.1371/journal.pone.0188644}}</ref>. Tractatio per 3—5 dies continuare oportet. [[Effectus adversus|Effectus adversi]] sunt per exemplum [[infectio]]nes, [[hypertensio]], retentio aquae ([[oedema]]).
Si effectibus careant, applicatio [[hormon adrenocorticotropinum|hormontis adrenocorticotropini]] ([[receptorium melanocortini|receptoria melanocortini]] stimulantis), denique [[plasmapheresis]]<ref>{{cite journal |authors=Cortese I., Chaudhry V., So Y. T., Cantor F., Cornblath D. R., Rae-GrantA. |title=Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology |journal=Neurology |year=2011 |month=Ian |volume=76 |issue=3 |pages=294-300 |url=https://pubmed.ncbi.nlm.nih.gov/21242498/}}, {{doi|10.1212/WNL.0b013e318207b1f6}}</ref> consideranda sunt. Rarius plasmapheresi [[cyclophosphamidum]] additum est.
